Covis Pharma Holdings S.a.r.l.
Zug Branch
Bahnhofstrasse 11
Zug
CH-6300
Tel: 011-41-748-04-04
Fax: 011-41-748-04-09
Website: http://www.covispharma.com/
24 articles with Covis Pharma Holdings S.a.r.l.
-
Covis Pharma Group Announces Executive Leadership Appointment in Canada
7/14/2022
Covis Pharma Group announced the appointment of Christine Poulin as Senior Vice President & General Manager, Canada, effective August 8, 2022.
-
Covis announced that the U.S. Food and Drug Administration has granted the company a hearing for its controversial drug Makena, which is intended to reduce preterm births.
-
Covis Pharma Provides Update on FDA Public Hearing for Makena®
6/14/2022
Covis Pharma GmbH, an affiliate of Group S.à r.l., announced that the U.S. Food & Drug Administration anticipates holding a meeting of the Obstetrics, Reproductive and Urologic Drugs Advisory Committee on October 17-19, 2022, to conduct a hearing about the future of Makena®.
-
BioSpace Movers & Shakers, Feb. 4
2/4/2022
Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers. -
Covis Pharma Group Announces Two Executive Management Team Appointments - Jan 31, 2022
1/31/2022
Covis Pharma Group, a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses, announced the joining of Michelle Lock as Chief Operating Officer, effective February 7, 2022, and the internal appointment of Sandy Loreaux as President, U.S. Business, with immediate effect.
-
Covis Enters Promotion and Distribution Agreement for Two Respiratory Medicines, Seebri® Breezhaler® and Ultibro® Breezhaler®, in Canada
1/5/2022
Covis Pharma Canada Ltd. is pleased to announce that it has entered into an Exclusive Promotion and Distribution Agreement with Novartis Pharmaceuticals Canada Inc., whereby Covis has been appointed as Novartis’ exclusive partner to promote and distribute PrSeebri® Breezhaler® and PrUltibro® Breezhaler® in Canada.
-
Covis Completes Acquisition of Global Respiratory Portfolio of Two Medicines from AstraZeneca
1/5/2022
Covis Pharma Group, a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses, announced that Covis Pharma GmbH has completed the acquisition of Eklira®, known as Tudorza® in the US and marketed as Bretaris® in some countries, and Duaklir®, marketed as Brimica® in some countries, from AstraZeneca.
-
Covis Pharma Group Announces Two Executive Management Team Appointments
12/7/2021
Covis Pharma Group, a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses, announced the appointment of Raghav Chari as Chief Innovation Officer and Nicolas Verbeke as Senior Vice President, Europe & International.
-
The acquisition of the medicines – which netted AstraZeneca $143 million in the geographies covered under the agreement – provides a significant boost to Covis’s respiratory portfolio.
-
Covis Significantly Strengthens Global Respiratory Portfolio Through Acquisition of Two Medicines from AstraZeneca
11/1/2021
Covis Pharma Group, a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses, announced that Covis Pharma GmbH has acquired Eklira®, known as Tudorza® in the US and marketed as Bretaris® in some countries, and Duaklir®, marketed as Brimica® in some countries, from AstraZeneca.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
New data in the European Heart Journal show ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in elderly patients
10/4/2021
Covis Pharma GmbH and Norgine B.V. announced data demonstrating the investigational anticoagulant reversal agent, ciraparantag, reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly patients, were published in the European Heart Journal, official journal of the European Society of Cardiology.
-
Makena injection currently remains on the market but is poised to be removed pending the outcome of the meeting. The final decision will be made in the public hearing.
-
Covis Pharma Joins Effort of March of Dimes to Support the Health of All Moms and Babies
4/14/2021
March of Dimes, the nation’s leading nonprofit fighting for the health of moms and babies, announced that Covis Pharma Group is joining the effort. Covis Pharma will be the Presenting Sponsor at all March of Dimes events in Massachusetts in 2021 and 2022, including the Massachusetts March for Babies, the Lawn Party, the Black Ties for Babies Gala, the Signature Chef’s Event, and the Falmouth Road Race. “This partnership will have a major imp
-
Covis Group Completes Acquisition of AMAG Pharmaceuticals
11/16/2020
Covis Group S.à r.l. announced the completion of its acquisition of AMAG Pharmaceuticals, Inc. through the successful tender offer for all of the outstanding shares of common stock of AMAG at $13.75 per share in cash and subsequent merger.
-
Covis Pharma B.V. Initiates Phase 3 Clinical Trial of Alvesco (Ciclesonide) Inhaler for the Treatment of COVID-19
5/19/2020
U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) filing to study the use of Alvesco in COVID-19 Study will evaluate the Safety and Efficacy of Alvesco in the Treatment of Non-hospitalized COVID-19 Patients Aged 12 and Above
-
BioSpace Movers & Shakers, April 24
4/24/2020
Biopharma and life sciences companies bolster their leadership teams and boards with this week's Movers & Shakers. -
Rajiv De Silva Joins Covis Pharma as Chairman of the Board of Directors
4/20/2020
Covis Pharma, a global specialty pharmaceutical company, today announced the appointment of Rajiv De Silva as the Chairman of the Board of Directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200420005414/en/ Rajiv De Silva Joins Covis Pharma as Chairman of the Board of Directors (Photo: Business Wire) De Silva is a proven b
-
AstraZeneca Continues to Divest Products, Sells Rights to RSV Drug to Sobi for $1.5 Billion
11/14/2018
Two weeks after reporting a 45 percent growth in revenue for the third quarter, compared to last year, Swedish Orphan Biovitrum AB (Sobi) has snapped up the U.S. rights to AstraZeneca’s respiratory drug, Synagis, a drug used to treat RSV in infants, for $1.5 billion. -
AstraZeneca is unloading rights to Alvesco (ciclesonide) to treat persistent asthma, and Omnaris and Zetonna (ciclesonide) to treat nasal symptoms associated with rhinitis. The company indicates that the rights cover markets outside the United States and the U.S. royalties for the drugs.